A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
Glioblastoma
Interventions
DRUG

CC-90010

Specified dose on specified days

DRUG

Temozolomide

Specified dose on specified days

RADIATION

Radiotherapy

Specified dose on specified days

Trial Locations (29)

2100

Local Institution - 501, Copenhagen

5000

Local Institution - 500, Odense

9100

Local Institution - 503, Aalborg

10075

Local Institution - 800, New York

15006

Local Institution - 311, A Coruña

20089

Local Institution - 202, Milan

20132

Local Institution - 201, Milan

28034

Local Institution - 304, Madrid

28040

Local Institution - 301, Madrid

28041

Local Institution - 300, Madrid

31008

Local Institution - 310, Pamplona

35128

Local Institution - 204, Padua

36312

Local Institution - 312, Vigo

37126

Local Institution - 200, Verona

41013

Local Institution - 309, Seville

46026

Local Institution - 305, Valencia

75185

Local Institution - 703, Uppsala

2333 ZA

Local Institution - 408, Leiden

1066 CX

Local Institution - 405, Amsterdam

3015 GD

Local Institution - 400, Rotterdam

3584 CX

Local Institution - 401, Utrecht

0424

Local Institution - 600, Oslo

08003

Local Institution - 306, Barcelona

08035

Local Institution - 302, Barcelona

08036

Local Institution - 303, Barcelona

08907

Local Institution - 307, Hospitalet de Llobregat, Barcelona

413 45

Local Institution - 702, Gothenburg

222 41

Local Institution - 701, Lund

171 64

Local Institution - 700, Solna

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04324840 - A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter